PANoptosis Opens New Treatment Options for Allergic Bronchopulmonary Aspergillosis

Overview

Journal J Allergy Clin Immunol Glob

Specialty Allergy & Immunology

Date 2024 Aug 22

PMID 39170913

Authors

Dalan Smallwood

Richard F Lockey

Narasaiah Kolliputi

Affiliations

Soon will be listed here.

Abstract

Background: Allergic bronchopulmonary aspergillosis (ABPA) is a rare airway disorder primarily affecting patients with asthma and cystic fibrosis. Persistent airway inflammation brought on by exacerbates the underlying condition and can cause significant respiratory damage. Treatments center on reducing inflammation with the use of corticosteroids and antifungals. PANoptosis is a new concept in the field of cell death and inflammation that posits the existence of cross talk and a master control system for the 3 programmed cell death (PCD) pathways, namely, apoptosis, pyroptosis, and necroptosis. This concept has revolutionized the understanding of PCD and opened new avenues for its exploration. Studies show that is one of the pathogens that is capable of activating PANoptosis via the Z-DNA binding protein 1 (ZBP1) pathway and plays an active role in the inflammation caused by this organism.

Objective: This article explores the nature of inflammation in ABPA and ways in which PCD could lead to novel treatment options.

Method: PubMed was used to review the literature surrounding infection-related inflammation and PANoptosis.

Results: There is evidence that apoptosis and pyroptosis protect against induced inflammation, whereas necroptosis promotes inflammation.

Conclusion: Experimental medications, in particular, necroptosis inhibitors such as necrosulfonamide and necrostatin-1, should be studied for use in the treatment of ABPA.

References

Rodrigues M . The Multifunctional Fungal Ergosterol. mBio. 2018; 9(5). PMC: 6143734. DOI: 10.1128/mBio.01755-18. View

Greenberger P . Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 2002; 110(5):685-92. DOI: 10.1067/mai.2002.130179. View

Saenz S, Taylor B, Artis D . Welcome to the neighborhood: epithelial cell-derived cytokines license innate and adaptive immune responses at mucosal sites. Immunol Rev. 2009; 226:172-90. PMC: 2683382. DOI: 10.1111/j.1600-065X.2008.00713.x. View

Khoury M, Gupta K, Franco S, Liu B . Necroptosis in the Pathophysiology of Disease. Am J Pathol. 2019; 190(2):272-285. PMC: 6983729. DOI: 10.1016/j.ajpath.2019.10.012. View

Zhu P, Ke Z, Chen J, Li S, Ma T, Fan X . Advances in mechanism and regulation of PANoptosis: Prospects in disease treatment. Front Immunol. 2023; 14:1120034. PMC: 9948402. DOI: 10.3389/fimmu.2023.1120034. View

Garth J, Reeder K, Godwin M, Mackel J, Dunaway C, Blackburn J . IL-33 Signaling Regulates Innate IL-17A and IL-22 Production via Suppression of Prostaglandin E during Lung Fungal Infection. J Immunol. 2017; 199(6):2140-2148. PMC: 5587395. DOI: 10.4049/jimmunol.1602186. View

OReilly A, Dunican E . The Use of Targeted Monoclonal Antibodies in the Treatment of ABPA-A Case Series. Medicina (Kaunas). 2022; 58(1). PMC: 8780696. DOI: 10.3390/medicina58010053. View

England E, Rees D, Scott I, Carmen S, Chan D, Chaillan Huntington C . Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction. Sci Rep. 2023; 13(1):9825. PMC: 10276851. DOI: 10.1038/s41598-023-36642-y. View

Ketelut-Carneiro N, Fitzgerald K . Apoptosis, Pyroptosis, and Necroptosis-Oh My! The Many Ways a Cell Can Die. J Mol Biol. 2021; 434(4):167378. DOI: 10.1016/j.jmb.2021.167378. View

10.

Zhang Q, Guo D, Wang F, Ding W . Necrosulfonamide (NSA) protects intervertebral disc degeneration via necroptosis and apoptosis inhibition. Eur Rev Med Pharmacol Sci. 2020; 24(5):2683-2691. DOI: 10.26355/eurrev_202003_20538. View

11.

Cao L, Mu W . Necrostatin-1 and necroptosis inhibition: Pathophysiology and therapeutic implications. Pharmacol Res. 2020; 163:105297. PMC: 7962892. DOI: 10.1016/j.phrs.2020.105297. View

12.

Banoth B, Tuladhar S, Karki R, Sharma B, Briard B, Kesavardhana S . ZBP1 promotes fungi-induced inflammasome activation and pyroptosis, apoptosis, and necroptosis (PANoptosis). J Biol Chem. 2020; 295(52):18276-18283. PMC: 7939383. DOI: 10.1074/jbc.RA120.015924. View

13.

Liu X, Zhou M, Mei L, Ruan J, Hu Q, Peng J . Key roles of necroptotic factors in promoting tumor growth. Oncotarget. 2016; 7(16):22219-33. PMC: 5008357. DOI: 10.18632/oncotarget.7924. View

14.

Ito Y, Takazono T, Obase Y, Fukahori S, Ashizawa N, Hirayama T . Serum Cytokines Usefulness for Understanding the Pathology in Allergic Bronchopulmonary Aspergillosis and Chronic Pulmonary Aspergillosis. J Fungi (Basel). 2022; 8(5). PMC: 9147526. DOI: 10.3390/jof8050436. View

15.

Sekiya M, Ueda K, Okazaki K, Kikuchi H, Kurata S, Oshima Y . A cyclopentanediol analogue selectively suppresses the conserved innate immunity pathways, Drosophila IMD and TNF-alpha pathways. Biochem Pharmacol. 2008; 75(11):2165-74. DOI: 10.1016/j.bcp.2007.12.020. View

16.

Bojanowski C, Bitoun J, Kolls J . An ALARMINg Type 2 Response in Cystic Fibrosis-The Key to Understanding ABPA?. Am J Respir Crit Care Med. 2023; 207(11):1418-1419. PMC: 10263133. DOI: 10.1164/rccm.202303-0580ED. View

17.

Cayrol C, Girard J . Interleukin-33 (IL-33): A critical review of its biology and the mechanisms involved in its release as a potent extracellular cytokine. Cytokine. 2022; 156:155891. DOI: 10.1016/j.cyto.2022.155891. View

18.

Maturu V, Agarwal R . Prevalence of Aspergillus sensitization and allergic bronchopulmonary aspergillosis in cystic fibrosis: systematic review and meta-analysis. Clin Exp Allergy. 2015; 45(12):1765-78. DOI: 10.1111/cea.12595. View

19.

Zhang J, Wei K . Necrosulfonamide reverses pyroptosis-induced inhibition of proliferation and differentiation of osteoblasts through the NLRP3/caspase-1/GSDMD pathway. Exp Cell Res. 2021; 405(2):112648. DOI: 10.1016/j.yexcr.2021.112648. View

20.

Koh W, Han J, Kim T, Lee K, Jang H, Kwon O . Allergic bronchopulmonary aspergillosis coupled with broncholithiasis in a non-asthmatic patient. J Korean Med Sci. 2007; 22(2):365-8. PMC: 2693610. DOI: 10.3346/jkms.2007.22.2.365. View